ASRT - Assertio Holdings, Inc.
IEX Last Trade
0.8888
-0.009 -1.069%
Share volume: 5,601
Last Updated: Thu 26 Dec 2024 08:19:10 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$0.90
-0.01
-1.06%
Fundamental analysis
22%
Profitability
2%
Dept financing
25%
Liquidity
74%
Performance
30%
Performance
5 Days
3.56%
1 Month
-10.51%
3 Months
-28.19%
6 Months
-27.60%
1 Year
-23.82%
2 Year
-78.53%
Key data
Stock price
$0.89
DAY RANGE
$0.87 - $0.91
52 WEEK RANGE
$0.78 - $1.80
52 WEEK CHANGE
-$20.35
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Daniel A. Peisert
Region: US
Website: assertiotx.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: assertiotx.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Assertio Holdings, Inc. provides medicines in neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the. treatment of migraine, nausea, photophobia, and phonophobia.
Recent news